[Phosphocreatine: thrombocyte aggregation in patients with stenocardia].
Phosphocreatine (Neoton produced by "Schapparelli Farmaceutici") was infused intravenously to 27 patients with CHD at a dose of 2000 mg: 13 patients with unstable and 10 patients with stable angina pectoris. Phosphocreatine blocked ADP-induced platelet aggregation in these patients, but had no significant effect on the platelet aggregation induced by collagen, platelet activating factor or serotonin.
E P
EP
Panchenko
S V
SV
Shalaev
M L
ML
Giorgadze
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000328:Adult; D000787:Angina Pectoris / Q000097:blood*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010725:Phosphocreatine / Q000008:administration & dosage / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors
D010975:Platelet Aggregation Inhibitors; D010725:Phosphocreatine; D000244:Adenosine Diphosphate
Fosfokreatin: agregatsiia trombotsitov u bol'nykh so stenokardieĭ.